Project Grant R21CA292295
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $403K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $215,311 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston (UTHealth) for the project "Preclinical Efficacy of GPR56 Antibody-Drug Conjugates and Combination Therapies for Triple-Negative Breast Cancer". The 24-month grant aims to develop and evaluate GPR56 antibody-drug conjugates (ADCs) as a novel targeted therapy for triple-negative breast cancer (TNBC),...
- This Project Grant award of $2,840,768 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to enhance the therapeutic efficacy and minimize side effects of the chemotherapy drugs cyclophosphamide (CPA) and doxorubicin (DOX) in treating triple-negative breast cancer (TNBC). The key objectives are to improve the metabolic activation of CPA and mitigate the cardiotoxicity of DOX by leveraging dual activation of the human constitutive androstane receptor (HCAR) and...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $719,799 to Health Research, Inc. at Roswell Park in Buffalo, NY to conduct research on the impact of metabolic adaptations on the tumor microenvironment in metastatic triple-negative breast cancer (TNBC). The key objectives are to investigate the bifunctional mechanisms of the PFKFB4 enzyme in regulating metabolic and genetic plasticity in the TNBC tumor microenvironment, and to...
- The National Cancer Institute awarded a $1,634,811 Project Grant to Natsar Pharmaceuticals, Inc. under the Cancer Treatment Research federal grant program (CFDA 93.395). The funding supports the drug development of RK-33, a small molecule inhibitor of the DDX3 RNA helicase, for the treatment of triple-negative breast cancers (TNBCs). TNBCs constitute 10-25% of all breast cancers and primarily affect younger women and African-American women, with limited treatment options. Preclinical studies...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $616,071 to The University of Texas Health Science Center at San Antonio (UTHSCSA) to develop novel adenosine receptor inverse agonists for the treatment of metastatic triple negative breast cancer (TNBC). The project, which runs from February 2025 to January 2030, involves a partnership between UTHSCSA and Riverwalk Therapeutics, Inc., a spin-off company incorporated by UTHSCSA....
- This $781,436 federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research by Cold Spring Harbor Laboratory to optimize anti-NMDAR (N-methyl-D-aspartate receptor) antibodies for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) establish an orthotopic mouse model of NMDAR-positive TNBC, 2) screen for anti-NMDAR antibodies that can effectively target NMDAR-positive TNBC cells while...
- This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), is focused on identifying the metabolic dysregulation and signaling pathways governing metastasis in triple-negative breast cancer (TNBC), and developing novel interventions to prevent this deadly disease. The $631,492 award to The University of Kentucky Research Foundation will support research to determine how the enzyme nicotinamide N-methyltransferase (NNMT) promotes...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,129 to The Johns Hopkins University to conduct research on leveraging a DDX3 inhibitor, RK-33, in combination with immunotherapy to treat triple-negative breast cancer (TNBC). The goal is to alter the tumor's metabolic environment in a way that enhances the effectiveness of immunotherapy, potentially leading to an "abscopal effect" where the treatment induces regression...
- This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...
- This federal Project Grant award, valued at $630,171.00, was provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395). The award aims to develop a first-in-class targeted radiopharmaceutical therapy (RPT) for the treatment of triple-negative breast cancer (TNBC), which lacks effective hormonal therapies. The key product being developed is a novel variable new antigen receptor (VNAR) binding domain from a nurse shark that targets the c-Met receptor,...